Investors

Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures in both the hospital and home settings.

NASDAQ: MRNS
$ 1.60 -0.06 (3.61%)
Day High: 1.71
Day Low:  1.52
Volume:    795,817
4:00 PM ET
Aug 26, 2016

Delayed ~20 min., by eSignal.